MedTrace Logo

Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease

NCT01147523 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-01-20

No results posted yet for this study

Summary

The primary aim of the study is the effect of spironolactone and vitamin E versus vitamin E on serum levels of adipokines 52 weeks post-treatment.

Conditions

Interventions

DRUG

Spironolactone/Vitamin E

Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks

Sponsors & Collaborators

  • Aristotle University Of Thessaloniki

    lead OTHER

Principal Investigators

  • Stergios A Polyzos, MD, MSc · Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece

  • Jannis Kountouras, MD, Prof · Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece

  • Efthimia Zafeiriadou, MD, PhD · Department of Radiology, Ippokration Hospital, Thessaloniki, Greece

  • Kalliopi Patsiaoura, MD, PhD · Department of Pathology, Ippokration Hospital, Thessaloniki, Greece

  • Evangelia Katsiki, MD · Department of Pathology, Ippokration Hospital, Thessaloniki, Greece

  • Aristidis Slavakis, MD, MSc · Department of Biochemistry, Ippokration Hospital, Thessaloniki, Greece

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-11-30
Completion
2011-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01147523 on ClinicalTrials.gov